Conversations on 
Twitter :
-
Can crowd-funding work for biotech? Key quote: "Drug development is hard."
@RyanMFierce and biotech investors participate -
Exelixis ($EXEL) slides on debt offering, analysts calling financing a disaster. Who is to blame?
Analysts and investors slamming both management and iBanker (Goldman) - Costly cancer meds: Is the market down on $SGEN due to unsustainable pricing?
@FierceBiotech: Pfizer taps biotech startup to tailor R&D of lupus, autoimmune drugs More | Follow @FierceBiotech
@JohnCFierce: Old pharma guys never die. They just go into venture capital. Now it's Jeff Kindler's turn. More | Follow @JohnCFierce
@RyanMFierce: Buzz on the street: Who thinks Icahn can succeed in biotech without two aces, Denner and Mulligan? More | Follow @RyanMFierce
> The venture capital industry, already suffering, might have to do without help from the deep pockets of California's pension manager known as CalPERS. Item
> Buzz: Can Carl Icahn, who is angling for board seats at Forest, win over biotech stockholders without two former aces who have left the billionaire investor to man a new hedge fund? Article
> Following similar efforts at Oxford and Harvard, the University of Cambridge plans to use $12.5 million for a stem cell research center. Report
> As part of the two drugmakers' multibillion-dollar diabetes alliance, AstraZeneca ($AZN) will pay $135 million to Bristol-Myers Squibb ($BMY) to gain some clout in decisions made about the portfolio at Bristol's recently acquired Amylin Pharmaceuticals. Item
Pharma News
@FiercePharma: HBR has an interesting piece by Pfizer's Susan Silbermann, on sales strategies in Latin America. More | Follow @FiercePharma
> Top 10 Drug Advertising Spends -- Q1 2012. Special Report
> India's Strides may put its Agila injectables unit on the block. Report
> Ex-Pfizer CEO Kindler joins up with VC firm. Item
> With patent clock ticking, Amgen plans to shutter Epogen plant. News
> High-flying Victoza sales push Novo's forecasts up. Story
@FierceMedDev: China's medical imaging market should exceed $2.5 billion by 2016, a new analysis concludes. Release | Follow @FierceMedDev
@MarkHFierce: Given Imaging experienced a mixed Q2. Meanwhile, the company is winding up for two regulatory submissions. More | Follow @MarkHFierce
@DamianFierce: In Q2, Alere's big revenue boost was negated by charges and costs related to its Dx recall. More | Follow @DamianFierce
> Exact Sciences seeks $50.2M in public offering. Story
> Former Home Diagnostics chief pleads guilty to insider trading. Report
> FDA dramatically limits use of Stryker's Wingspan brain stent. More
Vaccines News
> Sanofi readies defense as judge rules antitrust lawsuit can proceed. Story
> Tuberculosis vaccine may reverse Type 1 diabetes. Item
> Immatics' kidney cancer vaccine extends lives in trials. News
> Researchers discover malaria target. Article
> FDA lifts hold on Allergy Therapeutics' grass pollen allergy vax. Story
> CDC preps for emerging swine flu strain. More
Pharma Manufacturing News
> FDA tells drugmaker quality can't be added after production. More
> Chinese firm nailed with import alert over unsanitary plant. News
> Amgen to idle Epogen plant as sales fade away. Story
And Finally… A sad day for Groton? Pfizer seeks permits to demolish the drug giant's former R&D base in Connecticut. Article